A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases

He, Sirong; Gui, Jiajia; Xiong, Kun; Chen, Meiwan; Gao, Huile; Fu, Yao

doi:10.1186/s12951-022-01307-x

Cited by 73 publications

(35 citation statements)

References 185 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Direct exposure of LPS to the lungs not only triggers pulmonary inflammation but also promotes oxidative stress significantly. [ 21 ] Thus, the LPS‐induced ALI model was also selected, which is considered to be the inflammatory disease with high expression of iNOS/ROS. [ 6b,22 ] As shown in Figure S31, Supporting Information, the quantitative detection results of iNOS and ROS content showed that, the content of iNOS in the injured lungs of ALI mice was 25.8 × 10 −6 m , and there was almost no iNOS expression in healthy lungs.…”

Section: Resultsmentioning

confidence: 99%

A Universal Chemotactic Targeted Delivery Strategy for Inflammatory Diseases

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

Above 50% of deaths can be attributed to chronic inflammatory diseases; thus, the construction of drug delivery systems based on effective interaction of inflammatory factors with chemotactic nanoparticles is meaningful. Herein, a zwitterion‐based artificial chemotactic nanomotor is proposed for universal precise targeting strategy in vivo, where the high level of reactive oxygen species (ROS) and inducible nitric oxide synthase (iNOS) in inflammatory sites are used as a chemoattractant. Multidimensional static models, dynamic models, and in vivo models are established to evaluate chemotactic performance. The results show that the upregulated ROS and iNOS can induce the chemotaxis of nanomotors to diseased tissues in inflammation‐related disease models. Further, mesoscale hydrodynamics simulations are performed to explain the chemotactic behavior of the nanomotors. Such a chemotactic delivery strategy is expected to improve delivery efficiency and may be applicable to a variety of inflammatory diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

A Universal Chemotactic Targeted Delivery Strategy for Inflammatory Diseases

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…Pulmonary delivery of nanomedicine is currently among the most propitious drug delivery alternatives to the lungs via inhalation. Drug bioavailability in the lungs might be improved compared to oral and parenteral routes, as the administration excludes gastrointestinal metabolism and first-pass effects in the liver [ 17 , 18 , 19 , 20 ]. This alternative approach also provides direct drug depositions on the desired site [ 21 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Size-Controlled Preparation of Docetaxel- and Curcumin-Loaded Nanoemulsions for Potential Pulmonary Delivery

et al. 2023

View full text Add to dashboard Cite

Lung cancer is one of the deadliest pulmonary diseases in the world. Although docetaxel (DTX) has exhibited superior efficacy in lung cancer treatment, it has demonstrated numerous adverse effects and poor bioavailability. The natural product extract, curcumin (CCM), has reportedly reduced toxicity and synergistically improved DTX bioavailability. Nonetheless, the hydrophobic nature of DTX and CCM limits their clinical use. Nanoemulsion pulmonary delivery of DTX and CCM has demonstrated potential as a drug carrier to alleviate these drawbacks. The controlled preparation of inhalable DTX- and CCM-loaded nanoemulsions within the 100 to 200 nm range was explored in this study. A response surface methodology (RSM) based on a central composite design (CCD) was utilized to fabricate the desired size of the nanoemulsion under optimized conditions. Different process parameters were employed to control the size of the nanoemulsions procured through a high-energy emulsification technique. The size of the resultant nanoemulsions decreased with increasing energy input. The actual response according to the targeted sizes for DTX- and CCM-loaded nanoemulsion models exhibited excellent agreement with the predicted value at below 5% residual standard error under optimized conditions. The nanoemulsion of 100 nm particle size demonstrated better membrane permeability than their larger counterparts. Moreover, the formulations documented favorable physicochemical and aerodynamic pulmonary delivery properties and reduced toxicity in human lung fibroblast (MRC-5) cells. Hence, this tunable size of nanoemulsions could be a suitable alternative drug delivery for pulmonary diseases with increased local lung concentration.

show abstract

“…Respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD) and lung cancer, as well as respiratory infectious diseases, pneumonia and tuberculosis (TB), have always been a serious issue to human’s society, not only threatening their lives but also negatively affecting their socioeconomic status (Parray et al 2021 ). In the group of viral pathogens, we see corona virus, adenovirus, respiratory syncytial virus, influenza virus, rhinovirus, and measles, which are responsible for viral pneumonia (He et al 2022 ). With the aim of treating either infectious respiratory diseases or systemic disorders, inhaled therapeutics reduce both applied dose and cost of therapy with benefiting patients to administer drugs individually or at a nursing home (Parray et al 2021 ).…”

Section: Local and Systemic Delivery Of Dried-powder Biopharmaceuticalsmentioning

confidence: 99%

“…Oligopeptides, cytokines, enzymes, vaccines, mAbs, genes and clotting factors are categorized as biopharmaceuticals (Osman et al 2018 ). Pulmonary delivery of biopharmaceutics could be promising for preparing higher bioavailability than other routes while delivering lower dose of therapeutics (He et al 2022 ). Local pulmonary system provides a rapid onset of action when it comes to low molecular weight drugs (Faghihi et al 2021 ).…”

Section: Local and Systemic Delivery Of Dried-powder Biopharmaceuticalsmentioning

confidence: 99%

Recent progress in drying technologies for improving the stability and delivery efficiency of biopharmaceuticals

Emami

Shokooh

Yazdi

2022

J. Pharm. Investig.

View full text Add to dashboard Cite

Background Most biopharmaceuticals are developed in liquid dosage forms that are less stable than solid forms. To ensure the stability of biopharmaceuticals, it is critical to use an effective drying technique in the presence of an appropriate stabilizing excipient. Various drying techniques are available for this purpose, such as freeze drying or lyophilization, spray drying, spray freeze-drying, supercritical fluid drying, particle replication in nonwetting templates, and fluidized bed drying. Area covered In this review, we discuss drying technologies and their applications in the production of stable solid-state biopharmaceuticals, providing examples of commercially available products or clinical trial formulations. Alongside this, we also review how different analytical methods may be utilized in the evaluation of aerosol performance and powder characteristics of dried protein powders. Finally, we assess the protein integrity in terms of conformational and physicochemical stability and biological activity. Expert opinion With the aim of treating either infectious respiratory diseases or systemic disorders, inhaled biopharmaceuticals reduce both therapeutic dose and cost of therapy. Drying methods in the presence of optimized protein/stabilizer combinations, produce solid dosage forms of proteins with greater stability. A suitable drying method was chosen, and the process parameters were optimized based on the route of protein administration. With the ongoing trend of addressing deficiencies in biopharmaceutical production, developing new methods to replace conventional drying methods, and investigating novel excipients for more efficient stabilizing effects, these products have the potential to dominate the pharmaceutical industry in the future.

show abstract

A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases

Cited by 73 publications

References 185 publications

A Universal Chemotactic Targeted Delivery Strategy for Inflammatory Diseases

A Universal Chemotactic Targeted Delivery Strategy for Inflammatory Diseases

Size-Controlled Preparation of Docetaxel- and Curcumin-Loaded Nanoemulsions for Potential Pulmonary Delivery

Recent progress in drying technologies for improving the stability and delivery efficiency of biopharmaceuticals

Contact Info

Product

Resources

About